Senolytics After Chemo May Break the Glioblastoma Recurrence Cycle

Glioblastoma (GBM) carries a median survival of approximately 15 months despite aggressive multimodal treatment. A core reason for this dismal prognosis, the authors argue, has been systematically overlooked: standard-of-care therapies inadvertently create a reservoir of therapy-induced senescent (TIS) cells that actively remodel the tumor microenvironment (TME) in ways that promote recurrence rather than cure.

Cellular senescence is normally a tumor-suppressive mechanism governed by the p53/p21CIP1 and p16INK4A/Rb axes, which enforce stable cell cycle arrest in response to DNA damage, oncogenic stress, or telomere dysfunction. However, when induced en masse by ionizing radiation or temozolomide (TMZ), senescent cells persist and acquire the Senescence-Associated Secretory Phenotype (SASP)—a complex secretome including IL-6, IL-8, VEGF, and matrix metalloproteinases (MMPs). Acting via paracrine and autocrine signaling, SASP drives angiogenesis, extracellular matrix remodeling, immunosuppression, and the maintenance of glioblastoma stem cells (GSCs), collectively creating a permissive niche for tumor relapse. TMZ-driven senescence specifically activates SASP via NF-κB, while also repressing key DNA repair proteins (EXO1, MSH2, MSH6, RAD51), compounding genomic instability in surviving cells.

Different glial populations contribute distinctly to this senescent niche. Astrocytes, microglia, and oligodendrocyte precursor cells (OPCs) each respond differently to TIS and contribute specific pro-tumorigenic paracrine signals. The review also highlights epigenetic underpinnings: senescent GBM cells display a global loss of H3K27me3 repressive marks alongside focal H3K9me3 accumulation, keeping promoters of IL-6 and TGF-β open while silencing cell-cycle genes—a chromatin state that actively sustains the SASP.

To dismantle this recurrence machinery, the authors evaluate the 'one-two punch' strategy. The first punch uses standard genotoxic therapy to drive tumor cells into senescence; the second uses senolytics to selectively eliminate these arrested cells. Navitoclax (ABT-263), a Bcl-2/Bcl-xL inhibitor, disrupts the Senescent Cell Anti-Apoptotic Pathways (SCAPs) that protect senescent cells from death. Natural flavonoids Quercetin and Fisetin inhibit the PI3K/AKT/mTOR survival axis and exhibit senolytic activity with favorable CNS penetrance profiles. Preclinical evidence cited includes a murine GBM model by Salam et al. in which partial clearance of malignant senescent cells significantly altered the tumor ecosystem and improved survival in tumor-bearing mice.

Recognizing that rapid clearance of senescent cells can transiently release pro-inflammatory contents and trigger local neurotoxicity, the authors propose a novel integrative approach: coupling senolytic regimens with neuroprotective natural agents. This layered strategy aims to clear the senescent tumor reservoir while protecting surrounding neural tissue. Key translational challenges identified include optimal timing of senolytic administration relative to genotoxic therapy, hit-and-run dosing strategies to minimize off-target toxicity, and development of biomarkers for patient stratification based on TIS burden.